LATEST FROM IPOX^®

News

News and updates from IPOX^®, including media mentions, interviews, research and press releases.

Media mentions · Reuters

Reuters: IPOX^® VP Kat Liu Comments on Forgent Power's IPO Filing and Sector Risks

Reuters features IPOX^® VP Kat Liu’s analysis of Forgent Power Solutions’ robust IPO filing. Amid an 84% revenue surge, Liu discusses the strategic advantage of early 2026 timing and the constructive influence of strong peer performance. She provides critical insight into potential risks, including raw material costs and supply chain sensitivities, as the electrical equipment maker prepares for its NYSE debut.

January 10, 2026Kat Liu

Media mentions · Reuters

Reuters: IPOX^® Associate Muehlbauer comments on Eli Lilly’s backing of Aktis Oncology’s IPO

In a recent Reuters article, IPOX^® Associate Lukas Muehlbauer commented on Aktis Oncology’s upsized IPO, targeting a $945 million valuation with Eli Lilly as an anchor investor. Muehlbauer highlights that this backing validates Aktis’ technology and positions the firm as a strategic target in an M&A-driven sector. He views this as a positive signal for a selective biotech rebound in 2026, where investors increasingly favor proven, late-stage pipelines.

January 7, 2026

Media mentions · Bloomberg

Bloomberg: IPOX^® Analyst Lukas Muehlbauer Comments on the Evolution of European IPO Markets

Bloomberg features IPOX^® Analyst Lukas Muehlbauer on the trajectory of European listings since the 2021 IPO boom. Discussing InPost SA’s takeover offer, the article highlights the shift from a hype-driven seller’s market to a scrutiny-heavy buyer’s environment. Muehlbauer emphasizes that investors now prioritize credibility over "growth at all costs," fundamentally changing how new offerings are valued in the current market landscape.

January 7, 2026Lukas Muehlbauer

Media mentions · Benzinga

Benzinga: IPOX^® 100 U.S. Index (FPX) Leads with Medline Addition Amid IPO Revival

In a recent article, Benzinga featured the First Trust U.S. Equity Opportunities ETF (FPX), which tracks the IPOX^® 100 U.S. Index, for being the first to add Medline Industries after its massive IPO. The piece highlights the fund's systematic, rules-based methodology, noting a 40% gain this year and a five-star Morningstar rating. This underscores how IPOX^® indices provide investors with diversified, liquid access to top-performing new public companies like Medline.

December 26, 2025

Media mentions · Reuters

Reuters: IPOX^® VP Kat Liu highlights brand recognition in Andersen Group’s NYSE debut

In a recent article by Reuters, tax advisory firm Andersen Group saw its shares surge 31% during its NYSE debut. Kat Liu, Vice President at IPOX^®, noted that investors are responding to the firm's unique brand legacy and earnings stability. With a $2.3 billion valuation, Andersen plans to use its new public currency for aggressive global acquisitions, signaling a revitalized momentum in the U.S. IPO market following recent interest rate cuts.

December 18, 2025Kat Liu

Media mentions · Reuters

Reuters: IPOX^® Analyst Muehlbauer Discusses Wealthfront's IPO and Fintech Market Selectivity

IPOX^® Research Analyst Lukas Muehlbauer was featured in Reuters discussing Wealthfront’s $2.63 billion Nasdaq debut. While the fintech raised $484.6 million, its flat opening highlighted ongoing market caution. Muehlbauer noted that "investors are still selective," distinguishing between high-profile wins and mixed broader performance. His commentary underscores the critical nuance required when analyzing shifting sentiment within the recovering fintech IPO landscape.

December 12, 2025

Media mentions · Reuters

Reuters: IPOX^® CEO Josef Schuster Comments on Lumexa Imaging's IPO and Market Trends

In a recent Reuters article, IPOX^® CEO Josef Schuster analyzes the successful $462.5 million IPO of Lumexa Imaging amidst the year-end market rush. Schuster highlights that while investor appetite exists for the "right deal," there is notable caution regarding sectors with poor post-IPO returns, such as Silicon Valley-backed crypto and AI ventures. Read more about his insights on the current selective IPO landscape.

December 12, 2025Josef Schuster

Media mentions · Reuters & Equipment Finance News

Reuters & Equipment Finance News: IPOX^® Analyst Muehlbauer Comments on EquipmentShare.com IPO Filing

Construction tech firm EquipmentShare revealed significant revenue growth in its recent US IPO paperwork. IPOX^® Research Analyst Lukas Muehlbauer provided key insights on the filing, noting the company’s sensitivity to interest rates due to capital deployment for its rental fleet. Muehlbauer also discussed the broader market trend, suggesting companies are rushing filings to avoid potential volatility and uncertainty surrounding Federal Reserve leadership changes in 2026.

December 9, 2025

Media mentions · Reuters

Reuters: IPOX^® CEO Schuster Comments on Medline's 'Blockbuster' $55 Billion IPO Target

In a recent Reuters article, IPOX^® CEO Josef Schuster analyzes Medline’s targeted $55 billion listing, poised to be 2025’s largest IPO. Dr. Schuster highlights the deal as a critical test for market breadth beyond tech, describing the company as an "amazing American growth story." His commentary underscores the vital role of public markets in funding expansion as Medline seeks to raise over $5 billion in this blockbuster offering.

December 8, 2025

News

Stay ahead of the next listing.